Donepezil
- Generic Name
- Donepezil
- Brand Names
- Adlarity, Aricept, Namzaric
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29NO3
- CAS Number
- 120014-06-4
- Unique Ingredient Identifier
- 8SSC91326P
- Background
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other types of dementia.
Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with Memantine in 2014 to manage moderate and severe forms of Alzheimer's dementia. A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia. Though it does not alter the progression of Alzheimer's disease, donepezil is effective in managing the symptoms of its associated dementia.
- Indication
Donepezil, administered orally or via transdermal delivery system, is indicated for the treatment of dementia of the Alzheimer's type. It is also available as an extended-release capsule in combination with memantine for the treatment of moderate-to-severe dementia of the Alzheimer's type in patients previously stabilized on 10mg of donepezil hydrochloride once daily.
Off-label uses include the management of vascular dementia, Parkinson's Disease-associated dementia, and Lewy body dementia, amongst others.
- Associated Conditions
- Alzheimer's Disease (AD), Dementia With Lewy Body Disease, Dementia due to Parkinson's disease, Dementia of the Alzheimer's Type, Vascular Dementia (VaD), Moderate Alzheimer's Type Dementia, Severe Alzheimer's Type Dementia
Donepezil in Preventing Delirium in Hospitalized Elderly
- Conditions
- Postoperative ComplicationsDelirium
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2008-03-03
- Lead Sponsor
- Indiana University Health
- Target Recruit Count
- 30
- Registration Number
- NCT00182884
- Locations
- 🇺🇸
Methodist Hospital, Clarian Health Partners, Indianapolis, Indiana, United States
Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 149
- Registration Number
- NCT00174382
- Locations
- 🇨🇦
Pfizer Investigational Site, Regina, Saskatchewan, Canada
Antidepressant Medication Plus Donepezil for Treating Late-life Depression
- Conditions
- DepressionDementia
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2013-02-06
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 220
- Registration Number
- NCT00177671
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD Patients
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2013-11-20
- Lead Sponsor
- Eisai Korea Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00165750
- Locations
- 🇰🇷
Cheonnam University Hospital, Gwangju, Korea, Republic of
Alzheimer's Disease Long-term Follow-up Study (ALF Study)
- Conditions
- Alzheimer's Disease
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2021-12-30
- Lead Sponsor
- Eisai Korea Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT00165724
- Locations
- 🇰🇷
Yeungnam University Hospital, Daegu, Korea, Republic of
🇰🇷Changwon Fatima Hospital, Changwon, Korea, Republic of
🇰🇷Bobath Memorial Hospital, Bundang, Korea, Republic of
Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2012-05-04
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00165763
- Locations
- 🇵🇭
Memory Center, Quezon, Manila, Philippines
🇵🇭Subic Bay Medical Center, Olongapo, Zambales, Philippines
Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease
- Conditions
- Dementia, Vascular
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2011-04-01
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 974
- Registration Number
- NCT00165737
- Locations
- 🇺🇸
Neurological Associate of Albany PC, Albany, New York, United States
🇺🇸St. Francis Medical Center, Peoria, Illinois, United States
🇺🇸University of Texas Mental Sciences Institute, Houston, Texas, United States
A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020
- Conditions
- Alzheimer Disease
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2010-01-29
- Lead Sponsor
- Eisai Limited
- Registration Number
- NCT00165659
The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia
- Conditions
- Dementia With Parkinson's Disease
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2013-05-10
- Lead Sponsor
- Eisai Limited
- Registration Number
- NCT00165815
- Locations
- 🇮🇪
Belfast City Hospital, Belfast, Ireland
🇮🇪Unit 20 Black Poo Technology Centerl, Blackpool, Ireland
🇩🇪Parkinson Klinik Wolfach, Wolfach, Germany
Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 229
- Registration Number
- NCT00151398
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.